Not available
Quote | NewLink Genetics (NASDAQ:NLNK)
Last: | $ |
---|---|
Change Percent: | -2.47% |
Open: | $1.63 |
Close: | $1.58 |
High: | $1.65 |
Low: | $1.57 |
Volume: | 183,508 |
Last Trade Date Time: | 02/12/2020 04:48:19 pm |
News | NewLink Genetics (NASDAQ:NLNK)
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
Message Board Posts | NewLink Genetics (NASDAQ:NLNK)
Subject | By | Source | When |
---|---|---|---|
I see form t buying and selling on | 1grimtxn | investorshub | 03/02/2020 3:08:18 PM |
no qtly report yet? anybody? | 1grimtxn | investorshub | 02/27/2020 10:13:04 AM |
$NLNK back to $.50 | BottomBounce | investorshub | 02/15/2020 9:11:11 PM |
if newlink was attempting a vacine for the | 1grimtxn | investorshub | 02/05/2020 7:15:42 PM |
what announcement? | 1grimtxn | investorshub | 02/05/2020 7:05:09 PM |
News, Short Squeeze, Breakout and More Instantly...
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash ...